Carolyn Bertozzi is the Anne T and Robert M Bass Professor of Chemistry at Stanford University, an Investigator at the Howard Hughes Medical Institute, and Co-Director of Stanford ChEM-H.
She develops innovative technologies that open new avenues for biological discovery and therapeutic development. She launched the field of bioorthogonal chemistry, which has enabled many new experimental approaches in biological research, including imaging methods, chemoproteomics, and vivo drug targeting.
Inventions that have been translated to commercial settings include a technology for site-specific protein modification that is used in antibody-drug conjugates that are in human clinical trials, antibody-enzyme conjugates that are in preclinical development for cancer immune therapy, and a platform for tuberculosis detection at the point of care. A recent innovation is the design of lysosome targeting chimeras (LYTACs) for targeted degradation of extracellular proteins.
Professor Bertozzi holds three honorary doctorate degrees, from Brown University, Duke University and Freie University Berlin. She was elected to the National Academy of Sciences in 2005 at the age of 39, one of the youngest chemists in the institution’s history. She has also been elected to the American Academy of Arts and Sciences, the German Academy of Sciences Leopoldina, the National Academy of Medicine (former Institute of Medicine), National Academy of Inventors and is a Foreign Member of the Royal Society.
Her awards include the American Chemical Society’s Arthur C Cope Award, the Heinrich Wieland Prize, the Ernst Schering Prize, a MacArthur Foundation ‘genius grant’, the Lemelson-MIT Prize, and the Chemistry for the Future Solvay Prize. She has co-founded six biotechnology companies, advises several, and is a member of the Board of Directors of Eli Lilly and Company.